Censo Biotechnologies (Axol Bioscience Ltd.)

SfN Neuroscience 2024 - will you be there? Next month we're heading to Neuroscience 2024 in Chicago from 5th to 9th October. As world leaders in manufacturing iPSCs consistently and at scale, we are excited to be attending this event to learn about new developments as neuroscientists present new research but also to expand collaborations. At Axol we are all about collaboration and supporting researchers on their journey to making world-renowned discoveries and changing the landscape of drug discovery and development. Therefore, we are looking forward to seeing these new developments within the drug discovery market and to forming new connections with future potential collaborators and clients. Come along and talk to us on Booth #1370 if you want to discuss how iPSC-derived cells can power your drug discovery and research! You can also contact us at [email protected]. #iPSCs #NeurodegenerativeResearch #AlzheimersDisease #DrugDiscovery #SfN

Identifying and characterizing risk factors for Alzheimer's Disease (AD) using cellular models. The quest for better targeted therapies for treatment of AD remains ongoing. In a paper by Devadoss et al, it was very interesting to see how our axoCells™ Human iPSC-Derived Neural Stem Cells, were being used to identify and characterize leucine-rich repeat-containing protein 25 (LRRC25) as part of the effort to identify novel biological pathways for future targeting in Alzheimer's disease. In their paper, it was noted how the autophagy–lysosomal pathway (ALP), which LRRC25 regulates, has been seen to be involved in the degradation of long-lived proteins. In addition, reduced ALP activity has also been seen during aging resulting in protein aggregation and the generation of toxic protein species, a key phenomenon in AD pathology. Despite these discoveries, how LRRC25 may contribute to AD pathogenesis is completely unknown. The first step was to first determine whether is LRRC25 is expressed in neurons and the brain. Using our axoCells™ Human iPSC-Derived Neural Stem Cells as part of their study, Devadoss et al were able to show an increased expression of LRRC25. This showed that LRRC25 is altered in a cellular model of AD powered by our axoCells™. This is one step in the ongoing journey to uncovering novel biological pathways for future targeting in Alzheimer's disease and we at Axol continue to make our contributions to supporting researchers in their drug discovery efforts by providing axoCells iPSC-derived cells for use building better AD models. Key highlights of our axoCells™ include: • Phenotypic characterization, including morphology and key marker expression • Functional performance measured on a range of assays including electrophysiology, calcium imaging and neurite outgrowth • Designed for co-culture and other advanced in vitro models including microfluidics and organ-on-chip devices • High-quality manufacturing from our ISO 9001-accredited production facility The full paper can be found here: https://hubs.la/Q02PPdpV0 To find out how iPSC-derived neural stem cells can help your studies, contact us at [email protected]. #StemCells #iPSCs #AD

Are you looking to develop in vitro co-culture models for Alzheimer's Disease (AD)? Look no further than Axol. We can supply you with high-quality, functional astrocytes to help you achieve just that. With key roles in homeostasis and repair, astrocyte dysfunction has been implicated in the development of AD and it is therefore a key cell type to include an in-vitro model of AD. Our axoCells™ are designed with co-culture in mind and we've become the first choice for researchers looking to build in vitro co-culture models with multiple iPSC-derived cells for AD. Our axoCells Astrocytes are: • Assay-ready in 2 days • Demonstrate key marker expression (including GFAP and S100, with low levels of expression of Nestin (a NSC marker) and TUJ1 (a neuronal marker) • Can be used in co-culture with other neurons and neuroinflammatory cells for advanced in vitro AD models. Take a look at the axoCells Astrocytes section from our axoCells Catalog, outlining the key information including phenotypic characterization data, essential ordering information and a link to our user protocol: https://hubs.la/Q02PHbHY0 Looking to build human-relevant models for research or drug discovery? Contact us today at [email protected] and let's have a conversation! #iPSCs #Astrocytes #AlzheimersDisease #CoCulture #StemCells

It's great to see our distribution partners MineBio Life Sciences Limited participating in the 12th Annual Conference of Drug Toxicology held at the Everbright Convention & Exhibition Center in Shanghai, China last week. The theme of the conference was ‘Innovative Toxicology for the Future: Dual-Drive of Quality and Efficiency Leading New Drug Development’ and our products were among those showcased as providing comprehensive and integrated solutions for Chinese customers. The Chinese market for innovative solutions to drug development, such as IPSCs, is growing and at Axol, we place great value on collaboration in our efforts to support the wider drug discovery community. As a result, we've have a group of distribution partners who, we feel, align with our company values and are equally committed to the ultimate mission: unlocking iPSC technology for the global biopharma market to drive better research models and better therapies. Our distributors deliver our products (alongside excellent customer service) to their local networks, and we are happy to be partnered with MineBio who operate out of Shanghai to deliver our industry-leading iPSC products to researchers in China to met the growing demand for IPSC solutions. If you're working in China and would like to access our industry-leading iPSC products, make sure to get in contact directly with MineBio. If you have any questions, please get in contact at [email protected]. https://hubs.la/Q02PHfsC0 #IPSCs #China #biopharma #drugdiscovery

Looking to harness iPSC technology at scale? Let's have a discussion! Since the original methodology was developed in 2006 by Yamanaka et al., the use of iPSCs has grown around the world. But while the basic reprogramming and differentiation processes are well-characterized, it's a far more challenging endeavor to produce large batches of consistent, functional endpoint cells at the scales needed for drug discovery compound screens and disease models. That's why we're applying over a decade of expertise to assist biopharma organizations with their large-scale iPSC needs. Key highlights include: • Quality iPSC manufacturing capabilities from our ISO 9001-accredited production facility • Rigorous QC (and the current development of "functional QC" as standard) to enhance confidence in the cells • Extensive experience with the creation and banking of iPSCs for excellent batch-to-batch consistency in large scale projects To learn more, download our new B2B Directory: https://hubs.la/Q02PtWFf0 If you're looking to scale up your iPSC projects and need a consistent supply of functional cells, get in contact with us at [email protected] #iPSCs #StemCells #biopharma

Overcome the limitations in cellular modelling of human diseases with IPSCs... It is no doubt that developing cellular models for human diseases in vitro can be a challenging task. As highlighted in a Nature review article by Cerneckis et al, Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications, this task would require access to large quantities of cells. While some cell types can be easily isolated from living donors, for other types of cells such as brain and heart cells, they are largely unavailable. To combat this, many use rodent cells as the alternative. But these cells differ substantially to human cells and may not reflect certain human-specific cellular behaviors that would make the models relevant to human disease. We were excited to see how IPSCs were mentioned as key to overcoming the above limitations as they can be readily differentiated into hard-to-access cell types that possess human-specific phenotypes which are both physiologically and genetically relevant to the human disease model of interest. At Axol, we are committed to supporting the development of advanced in vitro systems from human donors to functional iPSC-derived cells that can be used for research, toxicity studies and drug discovery. Our axoCells can be used to build IPSC models of neurodegenerative diseases (such as Alzheimer's Disease, ALS, and Huntington's disease) as well as cardiac diseases (including arrythmias) that retain behaviors of the disease state! Click here to read the full paper: https://hubs.la/Q02Psx-80 If you would like to find out more about how our axoCells™ can help you develop better disease models, contact us at [email protected] You can also find out more about our products that meet your research needs in our catalog, click here to download the full catalog: https://hubs.la/Q02PswpY0 #Humandiseasemodelling #biopharma #iPSC #StemCells

Accelerate and de-risk drug discovery with human IPSCs from Axol. Human iPSCs are the gateway to better in vitro models for drug discovery and safety. As world leaders in manufacturing iPSCs consistently and at scale, we are excited to be attending the Drug Discovery 2024 meeting at the ExCeL in London, on 2nd-3rd October. Our presence at important events like these shows the great value we place on collaboration by meeting with existing partners and fostering new relationships with future collaborators. Meeting attendance also enables us to keep abreast of new developments and present our progress to the iPSC community. Our team will be on Booth B15, flying the flag for human iPSCs and how we're supporting the drug discovery market. Our scientists will also be presenting posters showing some of the recent developments here at Axol. Come and talk to us if you are interested in hearing how our axoCells™ can power your drug discovery models support your research needs! Alternatively, you can also email us at [email protected]. #ELRIG2024 #humaniPSCs #drugdiscovery #collaboration

#TechTuesday We're only too please to help. At Axol, we've spent more than a decade at the forefront of iPSC technology, adding to our bank of expertise in using iPSC-derived cells for drug discovery and research. Jessica Tilman PhD., took time out from her busy role as Scientific Group Leader at Axol, to speak with us about frequently asked questions for neurological immune cells. Jess is deeply involved in both microglia based product development and the delivery of service projects. She works in the cellular science group, and regularly participates in custom service projects, testing compounds on healthy and disease lines for disease specific phenotypes. Read the full interview here: https://hubs.la/Q02PkY7G0 If you are interested in using human iPSC-derived cells in your work, contact us at [email protected]. #TechTuesday #iPSCs #StemCells #Microglia

Commercial Partnership and B2B opportunities with Axol Bioscience. At Axol, collaboration is at the heart of what we do. Our commercial partners can access our decades of expertise in iPSC technology; and together we can provide a solution that excites, delights and retains customers. We manufacture iPSC-derived functional cells consistently and at scale, at our ISO 9001-accredited site in Roslin, Edinburgh, and can manufacture, supply and integrate high-quality iPSC-derived cells and lines drug discovery and research. Download our new B2B Directory to discover: • How we support CROs to onboard iPSC-based assays. - Partner with us to offer large scale iPSC-derived models for screening. We can supply functional iPSC derived cells for your development and service work, provide technical ‘know-how’ to fast track your platform integration, and support co-marketing to maximize your commercial reach. • How we work with microfluidic platform/MPS providers to integrate our functional axoCells™ with their systems. - We can work together with you to integrate axoCells into your platform and generate custom protocols and application notes for cells + platform • OEM/White label opportunities - We can manufacture iPSC-derived cells, media and supplements on your behalf, under your label • Licensing iPSC-derived cell lines - We can arrange a license agreement to provide iPSC-derived cell lines from patients with Parkinson’s and Huntington’s disease Download the B2B Directory here: https://hubs.la/Q02P56dw0 iPSC technology is transforming research and drug discovery. At Axol, we support research and drug discovery in neuroscience, pain and sensation, cardiovascular disease. If you are interested in partnering with us to unlock the benefits of iPSC technology for your customers, contact us at [email protected]. #iPSCs #StemCells #B2B #Opportunity

Are you working with iPSCs and advanced in vitro models? Are you based in Sweden, Norway, Finland or Denmark? Contact our new distribution partner BioNordika to access high-quality iPSC products! As an experienced company with ISO 9001 and 14001 certifications, we're excited to work with BioNordika. Make sure to contact them for your iPSC needs, and to support "Science Where You Are". https://hubs.la/Q02P4TLD0 https://hubs.la/Q02P4WFl0 #iPSCs #DistributionPartners #StemCells #biotech